Drug intelligence / Profile preview

lactobacillus plantarum MA2

Development stage: Preclinical
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

Lactobacillus plantarum MA2 is a functional probiotic strain originally isolated from traditional Chinese Tibetan kefir grains. It has demonstrated significant therapeutic potential in preclinical models for various conditions, including Alzheimer's disease (AD), non-alcoholic fatty liver disease (NAFLD), and hypercholesterolemia. Its mechanism of action involves the modulation of gut microbiota composition, improvement of the intestinal mucosal barrier (e.g., increasing claudin-1 expression), and reduction of systemic inflammation by inhibiting the LPS-TLR4/MYD88/NLRP3 signaling pathways. In AD models, MA2 and its derived exopolysaccharides (EPS) have been shown to inhibit amyloid-beta (Aβ42) aggregation and attenuate neuroinflammation. Additionally, the strain exhibits strong antioxidant properties both in vitro and in vivo, enhancing the activity of enzymes like superoxide dismutase and glutathione peroxidase.

Other names: L. plantarum MA2Lactobacillus plantarum MA2

Targets

TLR4 (Toll-like receptor 4)Aβ (Amyloid-beta peptides and aggregates)NLRP3 (Nod-like receptor family pyrin domain-containing protein 3)MYD88 (Myeloid differentiation primary response protein MyD88)

Beyond the preview

Go deeper on lactobacillus plantarum MA2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on lactobacillus plantarum MA2.

Explore the full profile